Chronic pain and psychedelics: a review and proposed mechanism of action
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
The development of chronic pain is a complex mechanism that is still not fully understood. Multiple somatic and visceral afferent pain signals, when experienced over time, cause a strengthening of certain neural circuitry through peripheral and central sensitization, resulting in the physical and emotional perceptual chronic pain experience. The mind-altering qualities of psychedelics have been attributed, through serotonin 2A (5-HT 2A) receptor agonism, to ‘reset’ areas of functional connectivity (FC) in the brain that play prominent roles in many central neuropathic states. Psychedelic substances have a generally favorable safety profile, especially when compared with opioid analgesics. Clinical evidence to date for their use for chronic pain is limited; however, several studies and reports over the past 50 years have shown potential analgesic benefit in cancer pain, phantom limb pain and cluster headache. While the mechanisms by which the classic psychedelics may provide analgesia are not clear, several possibilities exist given the similarity between 5-HT 2A activation pathways of psychedelics and the nociceptive modulation pathways in humans. Additionally, the alterations in FC seen with psychedelic use suggest a way that these agents could help reverse the changes in neural connections seen in chronic pain states. Given the current state of the opioid epidemic and limited efficacy of non-opioid analgesics, it is time to consider further research on psychedelics as analgesics in order to improve the lives of patients with chronic pain conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Exploring the brain network: A review on resting-state fMRI functional connectivity
van den Heuvel, M. P., & Hulshoff Pol, H. E. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.03.008 · Cited by 3,326
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Carhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00020 · Cited by 1,252
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206 · cited 1×
“112 115 There is also evidence that specific 5-HT 2A gene polymorphisms are associated with fibromyalgia, chronic widespread pain and pelvic pain, further demonstrating a significant role of the 5-HT 2A receptor in pain perception.”
Self-citationHuman hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172
González-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925 · cited 1×
“49 50 By contrast, although the non-hallucinogenic 5-HT 2A agonist lisuride increased the expression of c-fos in mouse SSC, it had no effect on period-1 , egr-1 or egr-2 expression.”
Functional reorganization of the default mode network across chronic pain conditions
Baliki, M. N., Mansour, A. R., Baria, A. T., & Apkarian, A. V. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106133 · Cited by 532 · cited 2×
“96 Review Figure 3 (COLOR) (A) A circular connectogram showing normally communication between distinct hubs.”
Hasler, F., Grimberg, U., Benz, M. A., Huber, T., & Vollenweider, F. X. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1640-6 · Cited by 451
Dynamic Resting-State Functional Connectivity in Major Depression
Kaiser, R. H., Whitfield-Gabrieli, S., Dillon, D. G., Goer, F., Beltzer, M., Minkel, J., Smoski, M., Dichter, G., & Pizzagalli, D. A. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.352 · Cited by 438
Johnson, M. W., Griffiths, R. R., Hendricks, P. S., & Henningfield, J. E. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.012 · Cited by 354
dos Santos, R. G., Osório, F. L., Crippa, J. A. S., Riba, J., Zuardi, A. W., & Hallak, J. E. C. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316638008 · Cited by 306
González-Maeso, J., Yuen, T., Ebersole, B. J., Wurmbach, E., Lira, A., Zhou, M., Weisstaub, N., Hen, R., Gingrich, J. A., & Sealfon, S. C. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-26-08836.2003 · Cited by 297
LYSERGIC ACID DIETHYLAMIDE: SIDE EFFECTS AND COMPLICATIONS
COHEN, S. (1960) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196001000-00005 · Cited by 287
Psychedelics and connectedness
Carhart-Harris, R. L., Erritzoe, D., Haijen, E., Kaelen, M., & Watts, R. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4701-y · Cited by 265
Hemington, K. S., Wu, Q., Kucyi, A., Inman, R. D., & Davis, K. D. (2016) · Brain Structure and Function · doi:10.1007/s00429-015-1161-1 · Cited by 220
Almeida, R. N. D., Galvão, A. C. D. M., da Silva, F. S., Silva, E. A. D. S., Palhano-Fontes, F., Maia-de-Oliveira, J. P., de Araújo, L.-S. B., Lobão-Soares, B., & Galvão-Coelho, N. L. (2019) · Frontiers in Psychology · doi:10.3389/fpsyg.2019.01234 · Cited by 177
Altered network hub connectivity after acute LSD administration
Müller, F., Dolder, P. C., Schmidt, A., Liechti, M. E., & Borgwardt, S. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2018.03.005 · Cited by 174
Nichols, C. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00405-5 · Cited by 163
Psychedelic Drugs in Biomedicine
Kyzar, E. J., Nichols, C. D., Gainetdinov, R. R., Nichols, D. E., & Kalueff, A. V. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.08.003 · Cited by 155 · cited 2×
“45”
Study of Lysergic Acid Diethylamide as an Analgesic Agent
KAST, E. C., & COLLINS, V. J. (1964) · Anesthesia & Analgesia · doi:10.1213/00000539-196405000-00013 · Cited by 142
Cui, H., Zhang, J., Liu, Y., Li, Q., Li, H., Zhang, L., Hu, Q., Cheng, W., Luo, Q., Li, J., et al. (2016) · Human Brain Mapping · doi:10.1002/hbm.23113 · Cited by 123
Karst, M., Halpern, J. H., Bernateck, M., & Passie, T. (2010) · Cephalalgia · doi:10.1177/0333102410363490 · Cited by 106
Philippi, C. L., Motzkin, J. C., Pujara, M. S., & Koenigs, M. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.10.005 · Cited by 93
MCKENNA, D. (1989) · Neuropsychopharmacology · doi:10.1016/0893-133x(89)90010-9 · Cited by 86
Do hallucinogens cause residual neuropsychological toxicity?
Halpern, J. H., & Pope, H. G. (1999) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00129-x · Cited by 82
Nichols, C. D., & Sanders‐Bush, E. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02515.x · Cited by 62
Mind-Body Interventions for Treatment of Phantom Limb Pain in Persons with Amputation
Moura, V. L., Faurot, K. R., Gaylord, S. A., Mann, J. D., Sill, M., Lynch, C., & Lee, M. Y. (2012) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/phm.0b013e3182466034 · Cited by 61
Müller, F., Liechti, M. E., Lang, U. E., & Borgwardt, S. (2018) · Progress in Brain Research · doi:10.1016/bs.pbr.2018.08.004 · Cited by 31
Resting functional connectivity in social anxiety disorder and the effect of pharmacotherapy
Doruyter, A., Lochner, C., Jordaan, G. P., Stein, D. J., Dupont, P., & Warwick, J. M. (2016) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2016.04.009 · Cited by 16
Cited by
Timmermann, C., Bauer, P. R., Gosseries, O., Vanhaudenhuyse, A., Vollenweider, F., Laureys, S., Singer, T., Antonova, E., & Lutz, A. (2023) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2022.11.006 · Cited by 150
Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis
Ko, K., Kopra, E. I., Cleare, A. J., & Rucker, J. J. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.09.168 · Cited by 150
Psychedelic perceptions: mental health service user attitudes to psilocybin therapy
Corrigan, K., Haran, M., McCandliss, C., McManus, R., Cleary, S., Trant, R., Kelly, Y., Ledden, K., Rush, G., O’Keane, V., et al. (2022) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-021-02668-2 · Cited by 84
“Curiously, the highest level of agreement for therapeutic indication in our survey was for chronic pain (34%), which has the least amount of clinical data [80].”
BackgroundPsychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
“Altered immune system function, mainly characterized by chronic lowgrade inflammation is associated with a range of psychiatric disorders (57, 249–251) and it remains an open question whether the potential anti-inflammatory activity of psychedelics will play a role in autoimmune disorders (252) or chronic pain (253, 2…”
BackgroundPepe, M., Hesami, M., de la Cerda, K. A., Perreault, M. L., Hsiang, T., & Jones, A. M. P. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108247 · Cited by 36
Metadata
- Authors
- Castellanos, J. P., Woolley, C., Bruno, K. A., Zeidan, F., Halberstadt, A., & Furnish, T.
- Venue
- Regional Anesthesia & Pain Medicine
- Publisher
- BMJ
- Published
- 2020-05-04
- Volume
- 45
- Issue
- 7
- Pages
- 486-494
- ISSN
- 1098-7339 (ISSN-L)
- 1532-8651
- OpenAlex
- W3023228010
- Cited by
- 119
- References
- 33
- FWCI
- 5.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.